Hypertension Found in Nearly Half of HIV Patients on HAART

Study reveals high blood pressure burden in HIV care

New research has found that hypertension is present in nearly half of patients undergoing highly active antiretroviral therapy (HAART) for HIV. The findings, reported in the European Medical Journal (EMJ), underscore a growing concern in HIV management: as antiretroviral treatment extends lives, cardiovascular risks are emerging as a major comorbidity.

The study, which analysed data from a cohort of HAART patients, found that 48% had elevated blood pressure readings. This prevalence is significantly higher than in the general population, suggesting that HIV infection and its treatment may contribute to hypertension risk.

Why HAART patients are at risk

Several factors are believed to drive this trend. Antiretroviral drugs, particularly older protease inhibitors, have been linked to metabolic changes that can raise blood pressure. Additionally, HIV itself causes chronic inflammation, which can damage blood vessels over time.

Lifestyle factors such as diet, physical inactivity, and smoking—common among some patient groups—may further compound the risk. The study's authors note that hypertension often goes undiagnosed in this population because routine HIV care has historically focused on viral suppression rather than cardiovascular health.

Implications for clinical practice

The findings suggest that blood pressure screening should become a standard part of HIV follow-up visits. Currently, many HIV clinics do not routinely measure blood pressure, missing opportunities for early intervention.

Experts argue that integrating hypertension management into HIV care could prevent heart attacks, strokes, and kidney damage in a vulnerable group. This would require training healthcare workers, ensuring access to affordable antihypertensive medications, and educating patients about lifestyle modifications.

A call for integrated care

The study adds to a growing body of evidence that HIV care must evolve beyond viral suppression alone. As patients live longer, managing non-communicable diseases like hypertension becomes essential to maintaining quality of life.

In India, where HIV prevalence remains significant, the findings carry particular weight. Public health programmes may need to adopt a more holistic approach, combining antiretroviral therapy with cardiovascular risk assessment. The authors stress that this is not just a clinical issue but a public health priority requiring policy support.

While the study does not specify the exact patient demographics or treatment regimens, the message is clear: hypertension is a silent threat that cannot be ignored in HAART patients. Regular monitoring, early detection, and prompt treatment could make a substantial difference.

Moving forward, researchers are likely to explore which specific antiretroviral drugs carry the highest hypertension risk and whether newer formulations are safer. For now, the onus is on healthcare providers to add blood pressure checks to every HIV consultation.